BrightSpring Health Services

BTSG

시가총액 US$120억

BrightSpring's shares surge 67.3% year to date, fueled by strong pharmacy and provider growth, improving profitability and a brighter 2026 outlook.

I believe BrightSpring Health Services' pharmacy and home-care businesses have a few ways to monetize their sizeable revenues into higher EBITDA over time. BTSG's new oncology distribution wins also grow their addressable market, which is why drug adoption is vital going forward. BTSG's recently acquired home-health branches also have interesting potential as their integration progresses.

Healthcare offers investors a potential combination of offense with forward earnings and defense with rising demand amid persistent macro-economic uncertainty. The healthcare sector is positioned for above-average long-term growth, supported by aging demographics, rising medical demand, and increased spending that's expected to outpace the broader economy. Strong forward revenue, EBITDA, and earnings growth demonstrate how select healthcare services and facilities companies can significantly outperform their sector peers.

LOUISVILLE, Ky., Oct. 01, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG) announced today that it plans to release its third quarter 2026 financial results on Friday, October 30, 2026, prior to the Company's earnings conference call, which will be held at 8:30 a.m. ET on the same day.

BrightSpring Health Services is expanding AI and automation across its operations, with early margin gains and more benefits expected later in 2026 and 2027.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

BrightSpring's faster growth, pharmacy and provider-service expansion, and improving margins contrast with OPCH's slower growth and chronic-therapy pressures.

BrightSpring Health Services NASDAQ: BTSG outlined its growth strategy across pharmacy and provider services at the Bernstein healthcare services conference, emphasizing specialty pharmacy expansion, home health acquisitions, technology investments and opportunities to integrate services for complex patients.

BTSG's stronger cash flow and lower leverage could give it more flexibility to pursue acquisitions and support future growth.

RDVT, BTSG and THC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 24th, 2026.